Tyra Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-16.9%projected annual EPS growth
Analyst Coverage
11analysts covering
FY EPS (est.)
-$2.67next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| BEACH301 Phase 2 Pediatric Achondroplasia Safety Sentinel Cohort Initial Results | 31 Dec 2026 |
| SURF303 Phase 2 LG-UTUC Initial Clinical Results | 31 Dec 2027 |
Monitoring Framework
Key Performance Indicators
SURF302 Phase 2 Trial Enrollment (Intermediate Risk NMIBC) Quarterly20.0Target: Complete enrollment for initial cohort
Cash Runway (Years) Quarterly2.2Target: Sustain operations into H2 2028
Total Cash and Marketable Securities Quarterly383.5MTarget: Maintain strong liquidity to fund multiple Phase 2 readouts
Watch Items
- SURF302 Phase 2 Initial Data ReadoutTrigger: August 2026 data releaseAction: Evaluate complete response (CR) rate (target >70-75% at 60mg dose) and safety/tolerability profile to validate FGFR3 selectivity.
- BEACH301 Phase 2 Pediatric Achondroplasia Safety Sentinel DataTrigger: Q4 2026 data releaseAction: Review initial safety and six-month height velocity data to confirm therapeutic window in pediatric patients.
- SURF303 Phase 2 LG-UTUC Registrational Study ProgressTrigger: First patient dosed in Q1 2026Action: Monitor enrollment velocity and site activation to project timeline for potential first NDA submission in 2027.
Research as of 19 Jun 2026